权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of MHC-restricted cell therapy using brain-tumor specific antigen and its chemicals

使用脑肿瘤特异性抗原及其化学物质开发 MHC 限制性细胞疗法

基本信息

批准号：
16209044
负责人：
YOSHIDA Jun
金额：
$ 32.28万
依托单位：
Nagoya University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (A)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2006
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16209044/
关键词：
Brain tumor MHC Immunotherapy Cell therapy ISO GMP 組織主要特異抗原

项目摘要

We have been developing MHC-restricted cell therapy using brain-tumor specific antigen and its chemicals. At first we identified X-linked X-linked inhibitor of apoptosis protein (XIAP), Aurora-B, c-Jun N-terminal kinase (JNK) and Fas as brain tumor-specific or associated antigens. Thereafter we designed their chemicals using methods of structure-based drug design or genome-information drug design, confirming their biological activities in cultured human glioma cells. Until now we operated genetic medicines in Japan for over 20 years and provided medical services to patients with formidable diseases such as malignant glioma and malignant melanoma. The results were succeeded to The Center for Genetic and Regenerative Medicine (CGRM) in our Hospital, which is an institute to put advanced medicine into practice in Nagoya University Hospital. There we are responsible for process development, validation, and GMP (Good Manufacturing Practice) production of a broad range of novel cell and gene therapies including dendritic cell vaccines, antigen-specific CTLs (cytotoxic T lymphocytes), plasmid DNA, liposomes with plasmid DNA, and bio-materials for regenerative medicine, in support of some clinical trials. In 2006 this CGRM gained ISO (International Organization for Standardization) 9001:2000 and 13485:2003 Accreditation. We became the first academic institute in Japan to achieve the ISO Quality. We opened clinical trials for patients with recurrent malignant glioma using MHC-restricted cells against some brain-tumor specific or associated antigen

我们一直在利用脑肿瘤特异性抗原及其化学物质开发 MHC 限制性细胞疗法。首先，我们将 X 连锁凋亡蛋白抑制剂 (XIAP)、Aurora-B、c-Jun N 末端激酶 (JNK) 和 Fas 鉴定为脑肿瘤特异性或相关抗原。此后，我们使用基于结构的药物设计或基因组信息药物设计的方法设计了他们的化学物质，确认了它们在培养的人类神经胶质瘤细胞中的生物活性。迄今为止，我们在日本经营基因药物已有20多年，为恶性胶质瘤、恶性黑色素瘤等疑难疾病患者提供医疗服务。该成果被本院遗传再生医学中心（CGRM）继承，该中心是名古屋大学附属医院的先进医学实践机构。在那里，我们负责各种新型细胞和基因疗法的工艺开发、验证和 GMP（良好生产规范）生产，包括树突状细胞疫苗、抗原特异性 CTL（细胞毒性 T 淋巴细胞）、质粒 DNA、带有质粒 DNA 的脂质体以及用于再生医学的生物材料，以支持一些临床试验。 2006 年，CGRM 获得了 ISO（国际标准化组织）9001:2000 和 13485:2003 认证。我们成为日本第一家获得 ISO 质量认证的学术机构。我们针对复发性恶性神经胶质瘤患者开展了针对某些脑肿瘤特异性或相关抗原的 MHC 限制性细胞的临床试验